Neuroendocrine Tumors

NEUROENDOCRINE TUMORS NEWS TIPS & FEATURES

New Drug Shows Improved Outcomes for Patients with Advanced Metastatic Mid-gut Neuroendocrine Tumors

January 23rd, 2017

New Drug Shows Improved Outcomes for Patients with Advanced Metastatic Mid-gut Neuroendocrine Tumors

A new therapy in development for the treatment of mid-gut neuroendocrine tumors, a rare type of cancer that occurs in the small intestine and colon, […]


FDA Designates Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma

August 12th, 2015

FDA Designates Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma

The U.S. Food and Drug Administration (FDA) has designated Azedra as a Breakthrough Therapy for the treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma […]


Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs

August 10th, 2015

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs

The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) […]


Afinitor® plus Herceptin® and Paclitaxel Effective in Advanced Hormone Receptor-Negative HER2-Positive Breast Cancer

February 5th, 2015

Afinitor® plus Herceptin® and Paclitaxel Effective in Advanced Hormone Receptor-Negative HER2-Positive Breast Cancer

The combination of Afinitor® (everolimus) plus Herceptin® (trastuzumab) paclitaxel appears effective for patients with advanced HER2-positive breast cancer that is hormone receptor (HR)-negative. These findings […]


Afinitor Provides Benefit in Advanced, HER2-Positive Breast Cancer

June 28th, 2013

Afinitor Provides Benefit in Advanced, HER2-Positive Breast Cancer

Among women with advanced HER2-positive breast cancer and resistance to Herceptin® (trastuzumab), a treatment regimen that included Afinitor® (everolimus) delayed cancer progression. The results of […]


Combination of Afinitor and Chemotherapy Shows Promise in Metastatic, Triple-Negative Breast Cancer

September 24th, 2012

Combination of Afinitor and Chemotherapy Shows Promise in Metastatic, Triple-Negative Breast Cancer

According to results presented at the 2012 Breast Cancer Symposium, the combination of Afinitor® (everolimus; also known as RAD001) and carboplatin may provide a benefit […]


Afinitor Approved for Advanced Breast Cancer

July 31st, 2012

Afinitor Approved for Advanced Breast Cancer

The U.S. Food and Drug Administration (FDA) has approved Afinitor® (everolimus) for use in combination with Aromasin® (exemestane) to treat postmenopausal women with advanced hormone-receptor […]


Afinitor Delays Breast Cancer Progression

December 14th, 2011

Afinitor Delays Breast Cancer Progression

Among postmenopausal women with advanced breast cancer that had become resistant to hormonal therapy, the combination of Afinitor® (everolimus) and Aromasin® (exemestane) delayed cancer progression […]


Afinitor Delays Progression of Advanced Breast Cancer

September 29th, 2011

Afinitor Delays Progression of Advanced Breast Cancer

Among postmenopausal women with advanced breast cancer that had become resistant to hormonal therapy, the combination of Afinitor® (everolimus) and Aromasin® (exemestane) delayed cancer progression […]


Adding Afinitor to Herceptin May Provide Breast Cancer Benefit

July 14th, 2011

Adding Afinitor to Herceptin May Provide Breast Cancer Benefit

For women with HER2-positive breast cancer that worsens in spite of treatment with Herceptin® (trastuzumab), treatment with a combination of Herceptin and Afinitor® (everolimus) may […]


More News →